Jpmorgan Chase & CO Pro Phase Labs, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Pro Phase Labs, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,802 shares of PRPH stock, worth $1,387. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,802Holding current value
$1,387% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding PRPH
# of Institutions
27Shares Held
1.71MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA656KShares$505,0790.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny215KShares$165,6340.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL179KShares$137,8640.0% of portfolio
-
Geode Capital Management, LLC Boston, MA161KShares$123,7650.0% of portfolio
-
Perritt Capital Management Inc Chicago, IL82.9KShares$63,8570.11% of portfolio
About ProPhase Labs, Inc.
- Ticker PRPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 16,024,400
- Market Cap $12.3M
- Description
- ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Lege...